Raia Drogasil (OTCMKTS:RADLY) Shares Gap Down – Time to Sell?

Raia Drogasil S.A. (OTCMKTS:RADLYGet Free Report)’s share price gapped down before the market opened on Tuesday . The stock had previously closed at $3.96, but opened at $3.82. Raia Drogasil shares last traded at $3.82, with a volume of 5,724 shares.

Raia Drogasil Stock Performance

The company has a debt-to-equity ratio of 0.99, a quick ratio of 0.58 and a current ratio of 1.41. The firm has a market cap of $4.83 billion and a P/E ratio of 73.40. The firm’s fifty day moving average price is $3.70 and its 200 day moving average price is $3.94.

Raia Drogasil (OTCMKTS:RADLYGet Free Report) last announced its quarterly earnings results on Tuesday, August 4th. The company reported $0.05 earnings per share for the quarter, hitting the consensus estimate of $0.05. The firm had revenue of $2.17 billion during the quarter, compared to analysts’ expectations of $2.32 billion. Raia Drogasil had a net margin of 2.97% and a return on equity of 18.20%. Sell-side analysts expect that Raia Drogasil S.A. will post 0.17 EPS for the current fiscal year.

About Raia Drogasil

(Get Free Report)

Raia Drogasil, now operating under the brand name RD Saúde, is a Brazilian healthcare and pharmacy retail company. It operates a nationwide network of pharmacies that sells prescription and over-the-counter medicines, personal-care products, cosmetics, health and wellness items, and convenience products.

The company also provides digital shopping and delivery services through its online channels, supporting customers with medication and health-related purchases. Its operations combine physical stores with e-commerce and other healthcare-related services, serving consumers throughout Brazil.

RD Saúde was formed in 2011 through the merger of Drogasil and Droga Raia, two pharmacy chains with roots dating back to the early twentieth century.

Recommended Stories

Receive News & Ratings for Raia Drogasil Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Raia Drogasil and related companies with MarketBeat.com's FREE daily email newsletter.